Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Attenuation of morphine withdrawal signs by the GABAB receptor agonist baclofen|
|Citation:||Life Sciences, 2001; 70(4):395-401|
|Publisher:||Pergamon-Elsevier Science Ltd|
|Sotiria Bexis, Jennifer Ong and Jason White|
|Abstract:||Abstract The present study examined the effect of the γ-aminobutyric acidB (GABAB) receptor agonist, baclofen on naloxone-induced withdrawal signs in morphine-dependent rats and modification by the antagonist, 3-aminopropyl-cyclohexylmethylphosphinic acid (CGP 46381). Morphine was administered via mini-osmotic pumps for 7 days to induce physical dependence. Baclofen (20 mg kg−1) decreased stereotyped head movements, chewing, chatter, ptosis and body weight loss, induced by naloxone (10 mg kg−1) in morphine-dependent rats. CGP 46381 (20 mg kg−1) reversed the effects exerted by baclofen on stereotyped head movements, ptosis, and weight loss and partially reversed the effect of baclofen on chewing. It can be concluded that baclofen has some potential in the treatment of opioid withdrawal and that GABAB receptors may be implicated in such a withdrawal.|
|Keywords:||Baclofen; Morphine-dependence; Morphine withdrawal; rat; Naloxone; CGP 46381|
|Appears in Collections:||Pharmacology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.